Loading...
Loading...
VKTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 36.6M |
| Operating I/L | -36.6M |
| Other Income/Expense | 11.6M |
| Interest Income | 11.5M |
| Pretax | -24.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -24.9M |
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for metabolic and endocrine disorders. The company's lead drug candidate, VK2809, is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis and NAFLD. Additionally, it is developing VK5211 for patients recovering from non-elective hip fracture surgery, VK0612 for type 2 diabetes, and VK0214 for X-linked adrenoleukodystrophy. These drug candidates are designed to address significant unmet medical needs and have the potential to generate revenue through successful clinical development and commercialization.
